APO Research
Talk to an analyst

APO RESEARCH · REPORT

Infectious Bursal Disease Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Infectious Bursal Disease Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026196 pages

Choose your research edition.

Industry ResearchInfectious Bursal Disease Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Infectious Bursal Disease Vaccine Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Infectious Bursal Disease Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infectious Bursal Disease Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Infectious Bursal Disease Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Infectious Bursal Disease Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Infectious Bursal Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Infectious Bursal Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Infectious Bursal Disease Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Infectious Bursal Disease Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Infectious Bursal Disease Vaccine market include Shandong Lvdu Biological Technology Co., Ltd., Ruipu Biopharmaceutical Co., Ltd., Qingdao Yibang Biological Engineering Co., Ltd., Plyco Bioengineering Co., Ltd., Merck, Harbin Pharmaceutical Group Biological Vaccine Co., Ltd., Zoetis, Elanco and Ceva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Infectious Bursal Disease Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Infectious Bursal Disease Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Infectious Bursal Disease Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Infectious Bursal Disease Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Infectious Bursal Disease Vaccine Segment by Company

Shandong Lvdu Biological Technology Co., Ltd.

Ruipu Biopharmaceutical Co., Ltd.

Qingdao Yibang Biological Engineering Co., Ltd.

Plyco Bioengineering Co., Ltd.

Merck

Harbin Pharmaceutical Group Biological Vaccine Co., Ltd.

Zoetis

Elanco

Ceva

Boehringer Ingelheim

Infectious Bursal Disease Vaccine Segment by Type

Live

Inactivated

Infectious Bursal Disease Vaccine Segment by Application

Veterinary Pharmacy

Online Sale

Others

Infectious Bursal Disease Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Infectious Bursal Disease Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Infectious Bursal Disease Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Infectious Bursal Disease Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Infectious Bursal Disease Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Bursal Disease Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infectious Bursal Disease Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Bursal Disease Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Infectious Bursal Disease Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infectious Bursal Disease Vaccine industry.

Chapter 3: Detailed analysis of Infectious Bursal Disease Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Infectious Bursal Disease Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Infectious Bursal Disease Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Infectious Bursal Disease Vaccine Industry Trends Table 2. Infectious Bursal Disease Vaccine Industry Drivers Table 3. Infectious Bursal Disease Vaccine Industry Opportunities and Challenges Table 4. Infectious Bursal Disease Vaccine Industry Restraints Table 5. Global Infectious Bursal Disease Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Infectious Bursal Disease Vaccine Revenue Share by Company (2021-2026) Table 7. Global Infectious Bursal Disease Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Infectious Bursal Disease Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Infectious Bursal Disease Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Infectious Bursal Disease Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Infectious Bursal Disease Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Infectious Bursal Disease Vaccine Company, Product Type & Application Table 13. Global Infectious Bursal Disease Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Infectious Bursal Disease Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Live Table 18. Significant Companies of Inactivated Table 19. Global Infectious Bursal Disease Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Infectious Bursal Disease Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Infectious Bursal Disease Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Infectious Bursal Disease Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Infectious Bursal Disease Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Infectious Bursal Disease Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Infectious Bursal Disease Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Infectious Bursal Disease Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Infectious Bursal Disease Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Infectious Bursal Disease Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Veterinary Pharmacy Table 30. Significant Companies of Online Sale Table 31. Significant Companies of Others Table 32. Global Infectious Bursal Disease Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Infectious Bursal Disease Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Infectious Bursal Disease Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Infectious Bursal Disease Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Infectious Bursal Disease Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Infectious Bursal Disease Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Infectious Bursal Disease Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Infectious Bursal Disease Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Infectious Bursal Disease Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Infectious Bursal Disease Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Infectious Bursal Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Infectious Bursal Disease Vaccine Sales by Region (2021-2026) & (K Units) Table 44. Global Infectious Bursal Disease Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Infectious Bursal Disease Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global Infectious Bursal Disease Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Infectious Bursal Disease Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Infectious Bursal Disease Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Infectious Bursal Disease Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Infectious Bursal Disease Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Infectious Bursal Disease Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Infectious Bursal Disease Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Infectious Bursal Disease Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Infectious Bursal Disease Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Infectious Bursal Disease Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Infectious Bursal Disease Vaccine Sales by Country (2021-2026) & (K Units) Table 57. Global Infectious Bursal Disease Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Infectious Bursal Disease Vaccine Sales by Country (2027-2032) & (K Units) Table 59. Global Infectious Bursal Disease Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Infectious Bursal Disease Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Infectious Bursal Disease Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Infectious Bursal Disease Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Infectious Bursal Disease Vaccine Sales Value Market Share by Country (2027-2032) Table 64. Shandong Lvdu Biological Technology Co., Ltd. Company Information Table 65. Shandong Lvdu Biological Technology Co., Ltd. Business Overview Table 66. Shandong Lvdu Biological Technology Co., Ltd. Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Shandong Lvdu Biological Technology Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio Table 68. Shandong Lvdu Biological Technology Co., Ltd. Recent Development Table 69. Ruipu Biopharmaceutical Co., Ltd. Company Information Table 70. Ruipu Biopharmaceutical Co., Ltd. Business Overview Table 71. Ruipu Biopharmaceutical Co., Ltd. Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Ruipu Biopharmaceutical Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio Table 73. Ruipu Biopharmaceutical Co., Ltd. Recent Development Table 74. Qingdao Yibang Biological Engineering Co., Ltd. Company Information Table 75. Qingdao Yibang Biological Engineering Co., Ltd. Business Overview Table 76. Qingdao Yibang Biological Engineering Co., Ltd. Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Qingdao Yibang Biological Engineering Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio Table 78. Qingdao Yibang Biological Engineering Co., Ltd. Recent Development Table 79. Plyco Bioengineering Co., Ltd. Company Information Table 80. Plyco Bioengineering Co., Ltd. Business Overview Table 81. Plyco Bioengineering Co., Ltd. Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Plyco Bioengineering Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio Table 83. Plyco Bioengineering Co., Ltd. Recent Development Table 84. Merck Company Information Table 85. Merck Business Overview Table 86. Merck Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Merck Infectious Bursal Disease Vaccine Product Portfolio Table 88. Merck Recent Development Table 89. Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Company Information Table 90. Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Business Overview Table 91. Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio Table 93. Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Recent Development Table 94. Zoetis Company Information Table 95. Zoetis Business Overview Table 96. Zoetis Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Zoetis Infectious Bursal Disease Vaccine Product Portfolio Table 98. Zoetis Recent Development Table 99. Elanco Company Information Table 100. Elanco Business Overview Table 101. Elanco Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Elanco Infectious Bursal Disease Vaccine Product Portfolio Table 103. Elanco Recent Development Table 104. Ceva Company Information Table 105. Ceva Business Overview Table 106. Ceva Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Ceva Infectious Bursal Disease Vaccine Product Portfolio Table 108. Ceva Recent Development Table 109. Boehringer Ingelheim Company Information Table 110. Boehringer Ingelheim Business Overview Table 111. Boehringer Ingelheim Infectious Bursal Disease Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Boehringer Ingelheim Infectious Bursal Disease Vaccine Product Portfolio Table 113. Boehringer Ingelheim Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Infectious Bursal Disease Vaccine Distributors List Table 117. Infectious Bursal Disease Vaccine Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Infectious Bursal Disease Vaccine Product Image Figure 2. Global Infectious Bursal Disease Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Infectious Bursal Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Infectious Bursal Disease Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Infectious Bursal Disease Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Infectious Bursal Disease Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Live Image Figure 10. Inactivated Image Figure 11. Global Infectious Bursal Disease Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Infectious Bursal Disease Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Infectious Bursal Disease Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Infectious Bursal Disease Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Infectious Bursal Disease Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Infectious Bursal Disease Vaccine Sales Value Share by Type (2021-2032) Figure 17. Veterinary Pharmacy Image Figure 18. Online Sale Image Figure 19. Others Image Figure 20. Global Infectious Bursal Disease Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Infectious Bursal Disease Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Infectious Bursal Disease Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Infectious Bursal Disease Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Infectious Bursal Disease Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Infectious Bursal Disease Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Infectious Bursal Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Infectious Bursal Disease Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Infectious Bursal Disease Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Infectious Bursal Disease Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Infectious Bursal Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Infectious Bursal Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Infectious Bursal Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Infectious Bursal Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Infectious Bursal Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Infectious Bursal Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Infectious Bursal Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Infectious Bursal Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Infectious Bursal Disease Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Infectious Bursal Disease Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Infectious Bursal Disease Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Infectious Bursal Disease Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Live
  • Inactivated
Applications
  • Veterinary Pharmacy
  • Online Sale
  • Others
Companies covered
  • Shandong Lvdu Biological Technology Co., Ltd.
  • Ruipu Biopharmaceutical Co., Ltd.
  • Qingdao Yibang Biological Engineering Co., Ltd.
  • Plyco Bioengineering Co., Ltd.
  • Merck
  • Harbin Pharmaceutical Group Biological Vaccine Co., Ltd.
  • Zoetis
  • Elanco
  • Ceva
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Infectious Bursal Disease Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Infectious Bursal Disease Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Infectious Bursal Disease Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Infectious Bursal Disease Vaccine Market Dynamics
  1. 2.1 Infectious Bursal Disease Vaccine Industry Trends
  2. 2.2 Infectious Bursal Disease Vaccine Industry Drivers
  3. 2.3 Infectious Bursal Disease Vaccine Industry Opportunities and Challenges
  4. 2.4 Infectious Bursal Disease Vaccine Industry Restraints
3 Infectious Bursal Disease Vaccine Market by Company
  1. 3.1 Global Infectious Bursal Disease Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Infectious Bursal Disease Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Infectious Bursal Disease Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Infectious Bursal Disease Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Infectious Bursal Disease Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Infectious Bursal Disease Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Infectious Bursal Disease Vaccine Company Product Type and Application
  8. 3.8 Global Infectious Bursal Disease Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Infectious Bursal Disease Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Infectious Bursal Disease Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Infectious Bursal Disease Vaccine Market by Type
  1. 4.1 Infectious Bursal Disease Vaccine Type Introduction
  2. 4.1.1 Live
  3. 4.1.2 Inactivated
  4. 4.2 Global Infectious Bursal Disease Vaccine Sales Volume by Type
  5. 4.2.1 Global Infectious Bursal Disease Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Infectious Bursal Disease Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Infectious Bursal Disease Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Infectious Bursal Disease Vaccine Sales Value by Type
  9. 4.3.1 Global Infectious Bursal Disease Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Infectious Bursal Disease Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Infectious Bursal Disease Vaccine Sales Value Share by Type (2021-2032)
5 Infectious Bursal Disease Vaccine Market by Application
  1. 5.1 Infectious Bursal Disease Vaccine Application Introduction
  2. 5.1.1 Veterinary Pharmacy
  3. 5.1.2 Online Sale
  4. 5.1.3 Others
  5. 5.2 Global Infectious Bursal Disease Vaccine Sales Volume by Application
  6. 5.2.1 Global Infectious Bursal Disease Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Infectious Bursal Disease Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Infectious Bursal Disease Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Infectious Bursal Disease Vaccine Sales Value by Application
  10. 5.3.1 Global Infectious Bursal Disease Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Infectious Bursal Disease Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Infectious Bursal Disease Vaccine Sales Value Share by Application (2021-2032)
6 Infectious Bursal Disease Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Infectious Bursal Disease Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Infectious Bursal Disease Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Infectious Bursal Disease Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Infectious Bursal Disease Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Infectious Bursal Disease Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Infectious Bursal Disease Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Infectious Bursal Disease Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Infectious Bursal Disease Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Infectious Bursal Disease Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Infectious Bursal Disease Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Infectious Bursal Disease Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Infectious Bursal Disease Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Infectious Bursal Disease Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Infectious Bursal Disease Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Infectious Bursal Disease Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Infectious Bursal Disease Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Infectious Bursal Disease Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Infectious Bursal Disease Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Infectious Bursal Disease Vaccine Sales Value Share by Country, 2025 VS 2032
7 Infectious Bursal Disease Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Infectious Bursal Disease Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Infectious Bursal Disease Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Infectious Bursal Disease Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Infectious Bursal Disease Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Infectious Bursal Disease Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Infectious Bursal Disease Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Infectious Bursal Disease Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Infectious Bursal Disease Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Infectious Bursal Disease Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Infectious Bursal Disease Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Infectious Bursal Disease Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shandong Lvdu Biological Technology Co., Ltd.
  2. 8.1.1 Shandong Lvdu Biological Technology Co., Ltd. Company Information
  3. 8.1.2 Shandong Lvdu Biological Technology Co., Ltd. Business Overview
  4. 8.1.3 Shandong Lvdu Biological Technology Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shandong Lvdu Biological Technology Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
  6. 8.1.5 Shandong Lvdu Biological Technology Co., Ltd. Recent Developments
  7. 8.2 Ruipu Biopharmaceutical Co., Ltd.
  8. 8.2.1 Ruipu Biopharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Ruipu Biopharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Ruipu Biopharmaceutical Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ruipu Biopharmaceutical Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
  12. 8.2.5 Ruipu Biopharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Qingdao Yibang Biological Engineering Co., Ltd.
  14. 8.3.1 Qingdao Yibang Biological Engineering Co., Ltd. Company Information
  15. 8.3.2 Qingdao Yibang Biological Engineering Co., Ltd. Business Overview
  16. 8.3.3 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
  18. 8.3.5 Qingdao Yibang Biological Engineering Co., Ltd. Recent Developments
  19. 8.4 Plyco Bioengineering Co., Ltd.
  20. 8.4.1 Plyco Bioengineering Co., Ltd. Company Information
  21. 8.4.2 Plyco Bioengineering Co., Ltd. Business Overview
  22. 8.4.3 Plyco Bioengineering Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Plyco Bioengineering Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
  24. 8.4.5 Plyco Bioengineering Co., Ltd. Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Infectious Bursal Disease Vaccine Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd.
  32. 8.6.1 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Company Information
  33. 8.6.2 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Business Overview
  34. 8.6.3 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
  36. 8.6.5 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Recent Developments
  37. 8.7 Zoetis
  38. 8.7.1 Zoetis Company Information
  39. 8.7.2 Zoetis Business Overview
  40. 8.7.3 Zoetis Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Zoetis Infectious Bursal Disease Vaccine Product Portfolio
  42. 8.7.5 Zoetis Recent Developments
  43. 8.8 Elanco
  44. 8.8.1 Elanco Company Information
  45. 8.8.2 Elanco Business Overview
  46. 8.8.3 Elanco Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Elanco Infectious Bursal Disease Vaccine Product Portfolio
  48. 8.8.5 Elanco Recent Developments
  49. 8.9 Ceva
  50. 8.9.1 Ceva Company Information
  51. 8.9.2 Ceva Business Overview
  52. 8.9.3 Ceva Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ceva Infectious Bursal Disease Vaccine Product Portfolio
  54. 8.9.5 Ceva Recent Developments
  55. 8.10 Boehringer Ingelheim
  56. 8.10.1 Boehringer Ingelheim Company Information
  57. 8.10.2 Boehringer Ingelheim Business Overview
  58. 8.10.3 Boehringer Ingelheim Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Boehringer Ingelheim Infectious Bursal Disease Vaccine Product Portfolio
  60. 8.10.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Infectious Bursal Disease Vaccine Value Chain Analysis
  2. 9.1.1 Infectious Bursal Disease Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Infectious Bursal Disease Vaccine Sales Mode & Process
  6. 9.2 Infectious Bursal Disease Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Infectious Bursal Disease Vaccine Distributors
  9. 9.2.3 Infectious Bursal Disease Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst